DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TREATMENTS
*****************************************************
#Post#: 2994--------------------------------------------------
Rituxan more effective than Gilenya, Tecfidera and comparable to
Tysabri
DIR By: agate
Date: August 14, 2020, 1:32 am
---------------------------------------------------------
More on this study, from Multiple Sclerosis News Today (August
11, 2020)--"Rituximab More Effective than Gilenya, Tecfidera and
Comparable to Tysabri, Study Finds":
HTML https://bit.ly/30ViwQX
#Post#: 3023--------------------------------------------------
(ACTRIMS/ECTRIMS) Low rituximab doses safer than, as effective
as higher ones
DIR By: agate
Date: September 15, 2020, 1:53 am
---------------------------------------------------------
From Multiple Sclerosis News Today (September 14, 2020),
"#MSVirtual2020: Low Rituximab Doses Are Safer [than], as
Effective as Higher Ones"--reporting on a presentation at the
recent ACTRIMS/ECTRIMS conference (September 11-13):
HTML https://bit.ly/3bXzIcp
#Post#: 3056--------------------------------------------------
(Abst.) Treatment of MS w/rituximab: A multicentric
Italian-Swiss experience
DIR By: agate
Date: October 17, 2020, 1:09 am
---------------------------------------------------------
From Multiple Sclerosis News Today (October 16,
2020)--"Treatment of multiple sclerosis with rituximab: A
multicentric Italian-Swiss experience":
HTML https://journals.sagepub.com/doi/abs/10.1177/1352458519872889
#Post#: 3269--------------------------------------------------
(Abst.) Reactivation of SARS-CoV-2 after rituximab in a patient
w/MS
DIR By: agate
Date: April 27, 2021, 12:45 am
---------------------------------------------------------
From PubMed (April 26, 2021)--"Reactivation of SARS-CoV-2 after
rituximab in a patient with multiple sclerosis":
HTML https://pubmed.ncbi.nlm.nih.gov/33895693/
#Post#: 3300--------------------------------------------------
Researchers tie severe immunosuppression to chronic COVID-19,
virus variants
DIR By: agate
Date: May 26, 2021, 1:19 am
---------------------------------------------------------
This article singles out rituximab as an instance of an
immunosuppressive drug that seems to be causing vulnerability to
infection with chronic COVID-19 and virus variants.
From JAMA (May 5, 2021)--"Researchers tie severe
immunosuppression to chronic COVID-19 and virus variants":
HTML https://bit.ly/3oSKQxO
#Post#: 3459--------------------------------------------------
(Cochrane review) Rituximab for people with MS
DIR By: agate
Date: November 9, 2021, 6:52 pm
---------------------------------------------------------
Abstract of a Cochrane review of rituximab for MS in PubMed
(November 9, 2021)--"Rituximab for people with multiple
sclerosis":
HTML https://pubmed.ncbi.nlm.nih.gov/34748215/
#Post#: 3719--------------------------------------------------
(Abst.) Safety and efficacy of Rituxan vs. Tecfidera in patients
w/RRMS or CIS...
DIR By: agate
Date: July 20, 2022, 7:16 pm
---------------------------------------------------------
From The Lancet (August 1, 2022)--"Safety and efficacy of
rituximab versus dimethyl fumarate in patients with
relapsing-remitting multiple sclerosis or clinically isolated
syndrome in Sweden: a rater-blinded, phase 3, randomised
controlled trial":
HTML https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00209-5/fulltext?rss=yes
#Post#: 3720--------------------------------------------------
(MedPage Today) Off-label drug lowers relapses in MS
DIR By: agate
Date: July 22, 2022, 12:42 am
---------------------------------------------------------
The study (see previous post) is discussed in an article in
MedPage Today (July 21, 2022)--"Off-Label Drug Lowers Relapses
in Multiple Sclerosis":
HTML https://www.medpagetoday.com/neurology/multiplesclerosis/99838
#Post#: 3872--------------------------------------------------
Some specialists make the case for rituximab to treat relapsing
MS
DIR By: agate
Date: December 17, 2022, 1:46 am
---------------------------------------------------------
From Neurology Today (December 15, 2022)--"Should Rituximab Be
Considered for Relapsing Forms of MS? Some Specialists Make the
Case for It":
HTML https://bit.ly/3jbEue3
Neurology Today is a publication of the American Academy of
Neurology.
#Post#: 3948--------------------------------------------------
(Abst.) Predictors of hospitalization due to infection in
rituximab-treated MS patients
DIR By: agate
Date: February 28, 2023, 1:36 am
---------------------------------------------------------
From PubMed, a study done in Norway is reported on (February 27,
2023)--"Predictors of hospitalization due to infection in
rituximab-treated multiple sclerosis patients":
HTML https://pubmed.ncbi.nlm.nih.gov/36842313/
*****************************************************
Page 2 of 4
DIR Previous Page
DIR Next Page